Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics - Narrative (Details)

v3.20.2
Acquisition of Pelican Therapeutics - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2016
May 31, 2016
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisition of Pelican Therapeutics                      
Discount rate           8.56%          
Accrued liabilities     $ 1,503,899     $ 1,503,899   $ 1,676,467      
Revenue     849,732 $ 6,439   2,344,777 $ 1,049,988        
Net loss (income)     (8,851,609) (6,194,598)   (19,598,145) (16,680,944)        
Net loss     $ 8,916,433 $ 6,330,913   $ 19,826,671 $ 17,094,899        
Pelican Therapeutics, Inc.                      
Acquisition of Pelican Therapeutics                      
Ownership interest in subsidiary     85.00%     85.00%   85.00%      
Pelican Therapeutics, Inc.                      
Acquisition of Pelican Therapeutics                      
Percentage of voting interests acquired in acquisition                 85.00% 80.00% 80.00%
Cash consideration         $ 200,000            
Percentage of non-controlling interest acquired     20.00%     20.00%          
Amount awarded from CPRIT grant   $ 15,200,000                  
Pelican Therapeutics, Inc. | Maximum                      
Acquisition of Pelican Therapeutics                      
Amount awarded from CPRIT grant $ 15,200,000                    
Pelican Therapeutics, Inc. | Stockholders                      
Acquisition of Pelican Therapeutics                      
Cash consideration         $ 300,000            
Pelican Therapeutics, Inc. | CEO                      
Acquisition of Pelican Therapeutics                      
Percentage of milestone payments that will be paid to related parties         22.70%